MetabolicResearch Market

Livagen

A synthetic tetrapeptide (Lys-Glu-Asp-Ala) from the Khavinson bioregulator family, studied for hepatic tissue bioregulation and liver geroprotection.

LiverDetoxificationBioregulatorKhavinson

Also referenced as: KEDA, Lys-Glu-Asp-Ala

Also appears in: Longevity

Price compare
12 tracked offers across 12 vendors · 5 dosages
Best trust-adjusted value: Peptide Supply Co · Strong trust · $1.89/mg
From
$1.89/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

Flatvs. Aug 10
Current low$1.89/mg
Market median$2.65/mg
Current coverage6 vendors
Observed window82 daily points
Lowest effective priceMarket median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Livagen crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence5 certificate records mentioning this compound or product name4 provider-linked · 5 exact product matches
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Metabolic

Primary research area: Metabolic. Also surfaces under Longevity for browsing and discovery.

Aliases
2

KEDA, Lys-Glu-Asp-Ala

Signal depth
Medium

No FDA label signal · 95 trials · 48 PubMed results

Preclinical
Research evidence

Current evidence for Livagen is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

Livagen has no clinical trials that name it and 48 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
Established
Plasma Physics and Controlled Fusion · 42 citationsProgress of the Keda Torus eXperiment Project in China: design and missionNuclear Fusion · 31 citationsOverview of Keda Torus eXperiment initial resultsReview of Scientific Instruments · 27 citationsDesign and construction of Keda Space Plasma Experiment (KSPEX) for the investigation of the boundary layer processes of ionospheric depletionsJournal ArticleEffects of Hydrogen Peroxide Soaking on the Seeds of Different Edible Bean Varieties.Journal ArticleMetabolic disorders are genetically correlated with the production and reproductive performance of dairy cows: a meta-analysis.Journal ArticleSuperior environmentally adaptable carbon doped and Co(3)O(4) nanoparticle modified carbon nitride materials activate PMS for rapid degradation of organic pollutants via non-radical pathways.
Evidence history
  1. 2026-07-25Anecdotal→PreclinicalBand Anecdotal → Preclinical; +48 PubMed
  2. 2026-07-24Preclinical→AnecdotalBand Preclinical → Anecdotal; -48 PubMed
  3. 2026-07-09PreclinicalFirst graded

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What is Livagen?

Livagen is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Ala (KEDA), classified as a liver-tissue bioregulator within the Khavinson peptide framework. It is theorized to modulate gene expression in hepatocytes to support liver function during aging.

How it works

  • Hepatic gene regulation — proposed to interact with DNA in liver cells and modulate transcription of genes involved in hepatic detoxification and regeneration (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
  • Chromatin remodeling — Khavinson et al. (2003) reported that the KEDA peptide can induce chromatin decondensation in hepatocyte nuclei from aged rats, suggesting epigenetic modulation (Bulletin of Experimental Biology and Medicine, 135(6):593–596)

Research status

  • Khavinson et al. (2003) showed Livagen-induced chromatin decondensation in aged rat hepatocytes (Bulletin of Experimental Biology and Medicine, 135(6):593–596)
  • Khavinson (2005) reviewed the broader bioregulator program (Gerontology, 51(2):70–75)
  • No independent Western clinical trials

Key considerations

  • The chromatin decondensation study is one of the more specific mechanistic data points in the Khavinson bioregulator family
  • Part of the same family as Cartalax, Pinealon, Cardiogen, and others
  • Available from research vendors as lyophilized powder or capsules